The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial).
 
Sarennya Pathmanandavel
No Relationships to Disclose
 
Megan Crumbaker
No Relationships to Disclose
 
Andrew On Wah Yam
No Relationships to Disclose
 
Christopher Rofe
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Macrogenics
 
Bao Ho
No Relationships to Disclose
 
Wai Ling Chan
No Relationships to Disclose
 
Shikha Sharma
No Relationships to Disclose
 
Adam James Hickey
No Relationships to Disclose
 
Kamonwan Kongrak
No Relationships to Disclose
 
Lalith Ratnayake
No Relationships to Disclose
 
Edmond Michael Kwan
Honoraria - Ipsen; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Pfizer
 
Arun Azad
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Serono; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); MedImmune (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Sanofi
 
Peter Eu
No Relationships to Disclose
 
Andrew Nguyen
No Relationships to Disclose
 
Anthony M. Joshua
Consulting or Advisory Role - AstraZeneca (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Louise Emmett
Honoraria - AstraZeneca; Janssen Oncology; Mundipharma
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; Mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)